Research programme: LEC/rituximab biobetter - Pivotal BioSciences

Drug Profile

Research programme: LEC/rituximab biobetter - Pivotal BioSciences

Alternative Names: PB 105

Latest Information Update: 24 Sep 2015

Price : $50

At a glance

  • Originator Pivotal BioSciences
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 23 Sep 2015 Preclinical trials in Cancer in USA (Parenteral) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top